Researchers target prolactin receptors to treat lupus

Researchers at the University of California, Riverside, and City of Hope have discovered a new strategy for treating systemic lupus erythematosus (SLE). The approach focuses on correcting an imbalance in prolactin hormone receptors found on disease‑causing immune cells. By targeting these receptors, the team was able to lower inflammatory molecules and reduce harmful immune cells while leaving normal immune cells intact. This finding offers a potential therapeutic direction for managing lupus‑related kidney damage.